Six Weeks Postpartum, Breastfeeding and Sure About Waiting Two Years: Applying the 2024 U.S. Medical Eligibility Criteria to Choose Contraception for a 31-Year-Old With Hypertension
[Student Name]
University of Phoenix
NRP/563: Management of Women's Health Issues
Week 4 Assignment
[Instructor Name]
[Date]
The patient is a composite written for a model paper.
Ms. J., a 31-year-old teacher, comes for her six-week postpartum visit. She is exclusively breastfeeding her daughter, delivered vaginally. She has chronic hypertension, well controlled on labetalol with blood pressure of 128/80 mm Hg today. She wants to wait at least two years before another pregnancy and asks what birth control is safe for her. This paper explains the counseling and prescribing.
The Eligibility Framework
CDC's eligibility guidance, revised in 2024, rates each method for people with specific conditions: category 1, no restriction; category 2, advantages generally outweigh risks; category 3, risks usually outweigh advantages; and category 4, unacceptable health risk (Nguyen et al., 2024). For a patient with several characteristics, each must be checked, and the most restrictive category guides the decision.
Her Characteristics
Ms. J. has three relevant characteristics: postpartum at six weeks, breastfeeding and chronic hypertension that is adequately controlled.
Estrogen-Containing Methods
Combined hormonal contraceptives, the pill, patch and ring, raise concerns on each count. In the early postpartum period, the risk of venous thromboembolism is elevated, and estrogen adds to it; the criteria restrict combined methods in the first weeks after delivery, especially with additional risk factors. Breastfeeding raises the question of effects on milk supply. And for hypertension, even when adequately controlled, combined hormonal contraceptives are category 3, because estrogen raises the risk of stroke and heart attack in people with hypertension (Nguyen et al., 2024). Combined methods are not a good choice for her.
Her blood pressure is controlled, but the estrogen in a pill would still add a risk her heart and vessels do not need.
Progestin-Only and Nonhormonal Methods
Progestin-only methods, including the implant, the levonorgestrel IUD and progestin-only pills, are generally category 1 or 2 for breastfeeding after the early postpartum weeks and for adequately controlled hypertension (Nguyen et al., 2024). The copper IUD, with no hormones, is category 1 for hypertension and breastfeeding. The injection is also an option, though with some considerations for bone density and a delay in return to fertility.
Effectiveness
Safety is one side of the choice; effectiveness is the other. The Contraceptive CHOICE Project followed 7,486 participants and found an unintended pregnancy rate of 4.55 per 100 participant-years with pills, patch or ring compared with 0.27 with long-acting reversible contraception, IUDs and implants (Winner et al., 2012). For someone certain she wants to avoid pregnancy for two years while caring for a newborn, long-acting methods offer the highest protection with the least daily effort.
Her Preferences
Ms. J. wants something she does not have to remember, does not want monthly bleeding if possible and is anxious about placement pain. We discuss the implant, which is inserted in the arm and may cause irregular bleeding, the levonorgestrel IUD, which often lightens periods, and the copper IUD, which may make them heavier. She chooses the levonorgestrel IUD.
Why Not Progestin-Only Pills
Progestin-only pills are safe for her but require taking a pill at the same time every day, and their effectiveness depends on that consistency. With a newborn and interrupted sleep, daily timing is hard. The CHOICE results for pills, patch and ring show how much effectiveness falls with typical use compared with long-acting methods (Winner et al., 2012).
Why Not the Implant
The implant is the most effective reversible method and would be category 1 or 2 for her (Nguyen et al., 2024). Its main drawback for Ms. J. is unpredictable bleeding, which she wanted to avoid. Had she preferred to avoid a pelvic procedure, the implant would have been an excellent choice.
The Copper IUD
The copper IUD offers hormone-free protection for up to 10 years and would suit someone who wants to avoid hormones entirely. It can make periods heavier and more painful, which led Ms. J. to prefer the levonorgestrel IUD, which tends to make bleeding lighter over time.
Return to Fertility
Ms. J. wants another child in about two years. Fertility returns promptly after IUD removal, unlike the injection, which can delay return by several months. This supports her plan to remove the device when she is ready.
Placement
IUDs can be placed at six weeks postpartum after confirming she is not pregnant and has no signs of infection. I discuss pain management options, obtain consent and place a 52 mg levonorgestrel IUD, which is effective for several years. I teach her to feel for the strings and to report pain, fever or unusual discharge.
Breastfeeding
I reassure her that progestin-only methods, including the levonorgestrel IUD, have not been shown to reduce milk supply meaningfully, and I encourage her to continue breastfeeding.
Screening for Safety
Contraceptive visits are also an opportunity to screen for partner violence and reproductive coercion, as recommended for women of reproductive age (U.S. Preventive Services Task Force et al., 2018). Ms. J. screens negative and says her partner supports her decision.
Blood Pressure
Her hypertension will continue to be managed; labetalol is compatible with breastfeeding. Her future pregnancy planning should include preconception counseling about blood pressure medications, since some, such as ACE inhibitors, must be avoided in pregnancy.
What She Needs to Know About the IUD
Some cramping and spotting are common in the first months. Bleeding usually decreases over time, and many users have very light periods or none after a year. She should call for severe pain, fever, a missing string or a feeling that the device has moved. It does not protect against sexually transmitted infections.
Postpartum Mood
At this visit I also screen for postpartum depression with the Edinburgh scale; her score is 6, and I remind her that symptoms can begin later in the first year.
Documenting Eligibility
The note records each characteristic considered, the eligibility category for the methods discussed and her informed choice, which supports the decision if questioned and helps future clinicians.
Partner Involvement
With her permission, I briefly discuss the plan with her husband, who came to the visit, so that he understands the method, the expected bleeding changes and the timing for trying to conceive again, which supports her decision at home.
Interpregnancy Interval
Waiting at least 18 months between delivery and the next conception is associated with better outcomes for mother and baby. Her plan to wait two years fits this, and the IUD makes the interval easy to maintain without daily effort, reminders or refills at the pharmacy.
Follow-Up
A string check in four to six weeks, or sooner for problems, and a reminder of when the IUD should be replaced.
Conclusion
Ms. J.'s postpartum status, breastfeeding and hypertension each count against estrogen-containing methods under the 2024 U.S. Medical Eligibility Criteria, while progestin-only and copper methods are appropriate. CHOICE data show long-acting methods are far more effective than pills, and her preferences led to a levonorgestrel IUD, placed today with teaching and follow-up.
References
Nguyen, A. T., Curtis, K. M., Tepper, N. K., Kortsmit, K., Brittain, A. W., Snyder, E. M., Cohen, M. A., Zapata, L. B., & Whiteman, M. K. (2024). U.S. medical eligibility criteria for contraceptive use, 2024. MMWR Recommendations and Reports, 73(4), 1-126. https://doi.org/10.15585/mmwr.rr7304a1
U.S. Preventive Services Task Force, Curry, S. J., Krist, A. H., Owens, D. K., Barry, M. J., Caughey, A. B., Davidson, K. W., Doubeni, C. A., Epling, J. W., Jr., Grossman, D. C., Kemper, A. R., Kubik, M., Kurth, A., Landefeld, C. S., Mangione, C. M., Silverstein, M., Simon, M. A., Tseng, C.-W., & Wong, J. B. (2018). Screening for intimate partner violence, elder abuse, and abuse of vulnerable adults: US Preventive Services Task Force final recommendation statement. JAMA, 320(16), 1678-1687. https://doi.org/10.1001/jama.2018.14741
Winner, B., Peipert, J. F., Zhao, Q., Buckel, C., Madden, T., Allsworth, J. E., & Secura, G. M. (2012). Effectiveness of long-acting reversible contraception. New England Journal of Medicine, 366(21), 1998-2007. https://doi.org/10.1056/NEJMoa1110855
How this NRP 563 Week 4 example is structured
The NRP/563 Week 4 work usually addresses contraceptive counseling and prescribing. This paper shows the eligibility criteria working on a real combination of conditions, pairs safety with effectiveness evidence and keeps the patient's preferences at the center of the choice. Students search this week as NRP 563 Week 4, NRP563 Wk 4 or NRP/563 Wk 4; all three are the same assignment.
NRP/563 Week 4 questions, answered
What does NRP/563 Week 4 usually ask for?
Many sections ask students to counsel a patient on contraception and prescribe a method, applying the U.S. Medical Eligibility Criteria to her health conditions.
What are the U.S. Medical Eligibility Criteria?
CDC guidance rating each contraceptive method from category 1 (no restriction) to category 4 (unacceptable health risk) for people with specific health conditions or characteristics.
Are estrogen-containing methods safe after delivery?
Not in the first weeks postpartum, when clot risk is high, and they may also affect milk supply; they are also restricted in people with hypertension, so the criteria must be checked for each condition.
Write yours, or have the desk draft it
This paper is an original model document written by our desk, not a submitted student paper and not an official University of Phoenix document. Read it for the moves, then write your own to the instructions in your classroom. If you want one built to your exact prompt and rubric, the first custom sample is free and arrives in 24 to 48 hours.